Viral safety of haemophilia treatment products

Annals of Medicine

Volumn 32, Issue 7, 2000, Pages 485-492

  Teitel, J M ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Blood components; Haemophilia; Hepatitis; HIV; Screening; Transfussion; Viral inactivation; Viral transmission

Indexed keywords

BLOOD CLOTTING FACTOR; CHOLIC ACID; ORGANIC SOLVENT; PHOTOSENSITIZING AGENT; POLYSORBATE 80; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; THIOCYANATE SODIUM; TRIBUTYL PHOSPHATE; TRITON X 100; VIRUS ANTIBODY; VIRUS DNA;

ARTICLE; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD SAMPLING; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; DRUG SYNTHESIS; GENE THERAPY; GENETIC RECOMBINATION; HEALTH CARE COST; HEATING; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS A VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; PARVOVIRUS; PASTEURIZATION; PRION DISEASE; PRIORITY JOURNAL; SCREENING TEST; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0033766582     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890009002024     Document Type: Article

References (61)

1. Hemophilia: The clinical use of antihemophilic globulin
2. Bovine antihaemophilic globulin in the treatment of haemophilia
3. Preparation of human plasma fraction rich in prothrombin, proconvertin, stuart factor and PTC and a study of its activity and toxicity in rabbits and man
4. Production of high potency concentrates of antihemphilic globulin in a closed bag system: Assay in vitro and in vivo
5. Management of patients with inherited coagulation defects
6. Hemolysis caused by factor VIII concentrates
7. Thrombogenic materials in prothrombin complex concentrates
8. Asymptomatic liver disease in haemophiliacs
9. Estimation of the probability of post transfusion hepatitis in hemophilia treatment
10. Erythrocyte P antigen: Cellular receptor for B19 parvovirus
11. Parvovirus B19 and erosive polyarthritis
12. Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent
13. Polyarteritis nodosa and parvovirus B19
14. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia
15. Chronic bone marrow failure due to persistent B19 parvovirus infection
16. Parvovirus B19-associated haemophagocytic syndrome with lymphadenopathy resembling histiocytic necrotizing lymphadenitis (Kikuchi's disease)
17. Parvovirus B19 and acute hepatitis in adults
18. B19 parvovirus with-stands 'super heating' in antihemophilic concentrates
19. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction
20. Incidence of human parvovirus B19 DNA detection in blood donors
21. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates
22. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery
23. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses
24. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients
25. Hepatitis A virus infections associated with clotting factor concentrate in the United States
26. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool
27. An outbreak of hepatitis A among South African patients with hemophilia: Evidence implicating contaminated factor VIII concentrates as the source
28. Hepatitis A transmission by factor IX concentrates
29. Hepatitis A among persons with hemophilia who received clotting factor concentrate - United States, September-December 1995
30. Hepatitis G viral RNA in serum and in peripheral blood mononuclear cells and its relation to HCV-RNA in patients with clotting disorders
31. Natural history of the TT virus infection through follow-up of TTV DNA-positive multiple-transfused patients
32. Global distribution of transfusion-transmitted virus
33. Presence of a newly described human DNA virus (TTV) in patients with liver disease
34. TT virus is present in a high frequency of Italian hemophilic patients transfused with plasma-derived clotting factor concentrates
35. Detection of TT virus DNA in plasma-derived clotting factor concentrates
36. The incidence of SEN virus infection in transfusion-associated hepatitis
37. Directed, paid, and self donors
38. Improving the safety of transfusion therapy
39. Anti-HCV screening and plasma fractionation: The case against
40. The risk of transfusion-transmitted viral infections
41. Postransfusion hepatitis B
42. Transmission of hepatitis B from hepatitis-B-seronegative subjects
43. Testing plasma pools for markers of viral contamination: The UK experience
44. Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase
45. Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection
46. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting
47. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA
48. Theoretical considerations on viral inactivation or elimination
49. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
50. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
51. Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration
52. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrate
53. Inactivation of viruses in blood and plasma products
54. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations
55. Successful clinical use of a plasma-derived, dual virus inactivated factor VIII concentrate incorporating solvent-detergent and dry heat treatment
56. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates
57. A double virus-inactivated factor VIII preparation: Validation and biochemical characteristics
58. The second year report of the national surveillance for haemophilia patients in Japan
59. Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America
60. Canadian hemophilia registry: HIV, HCV, and mortality
61. The ever changing needs of those with longterm HIV infection